CVAC

EQS-News: CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Retrieved on: 
Friday, November 11, 2022

TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.

Key Points: 
  • TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.
  • Preliminary results from the completed Phase 1 expansion study in patients with PD-1 refractory melanoma confirm a robust safety profile of CV8102 as a single agent and in combination with anti-PD-1 antibodies.
  • The data we collected in the heavily pretreated patients of our Phase 1 expansion study further confirm the safety and immuno-modulatory activity of CV8102, said Ulrike Gnad-Vogt, interim Chief Development Officer at CureVac.
  • The Phase 1, open-label, dose escalation and expansion study of CV8102 aims to assess safety, tolerability and efficacy of CV8102 as a single agent and in combination with licensed PD1-antibodies.

DGAP-News: CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Key Points: 
  • CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
    The issuer is solely responsible for the content of this announcement.
  • The CV0501 study follows the start of a Phase 1 study in March 2022 that evaluates an unmodified second-generation COVID-19 vaccine candidate CV2CoV, encoding for the original virus variant.
  • The comprehensive approach to evaluate both an unmodified and a modified, second-generation vaccine candidate against COVID-19 is expected to identify the best-performing candidate for later-stage clinical development.
  • CV0501 is CureVacs first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK.

DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Retrieved on: 
Thursday, August 18, 2022

In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.

Key Points: 
  • In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Moving into the second half of 2022, we are further broadening our mRNA technology platform and advancing our programs in prophylactic vaccines as well as executing on our core strategy in oncology.
  • CureVac is delivering on its previously announced 2022 clinical development program in prophylactic vaccines by initiating a Phase 1 study with the modified COVID-19 mRNA vaccine candidate CV0501.
  • In the first quarter of 2022, CureVac received a 10 million milestone payment related to the start of the seasonal influenza clinical trial.

DGAP-News: CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Retrieved on: 
Tuesday, July 5, 2022

CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.

Key Points: 
  • CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.
  • The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTechs SARS CoV-2 mRNA vaccine, among others.
  • CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health.
  • This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology.

DGAP-News: CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

Retrieved on: 
Wednesday, June 8, 2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

Key Points: 
  • CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
    The issuer is solely responsible for the content of this announcement.
  • CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
    TBINGEN, Germany/ AMSTERDAM, Netherlands June 8, 2022 CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.
  • Frames FramePro platform identifies structural changes within the cancer genome that give rise to new open reading frames.
  • The strong anti-tumor immune response elicited by Frame vaccines may contribute to major clinical benefits for patients with diverse forms of cancer.

DGAP-News: CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen

Retrieved on: 
Wednesday, June 8, 2022

CureVac is pleased to welcome Myriam Mendila to this key role.

Key Points: 
  • CureVac is pleased to welcome Myriam Mendila to this key role.
  • Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.
  • "We would like to sincerely thank Klaus for his leadership across several strategically decisive projects.
  • We thank him for his contributions to CureVac and wish him well for his next professional steps."

DGAP-News: CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

Retrieved on: 
Wednesday, May 25, 2022

Our financial position in the first quarter of 2022 was still impacted by effects related to prior commitments for our first-generation vaccine candidate, CVnCoV.

Key Points: 
  • Our financial position in the first quarter of 2022 was still impacted by effects related to prior commitments for our first-generation vaccine candidate, CVnCoV.
  • Looking forward, we expect the impact of these commitments to subside over the rest of the year, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Over the quarter, CureVac became eligible to a 10 million milestone payment related to the start of the seasonal influenza clinical trial.
  • 4.7 million of this milestone were recognized pro rata as revenue in the first quarter of 2022.

DGAP-News: CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

Retrieved on: 
Wednesday, May 25, 2022

Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies.

Key Points: 
  • Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies.
  • To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.
  • myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types.
  • myNEO is a Belgian biotech company that focuses on the development of immunotherapies finetuned against the tumour of cancer patients.

DGAP-News: CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

Retrieved on: 
Thursday, April 21, 2022

The preclinical study, conducted in collaboration with the Friedrich-Loeffler-Institut, Germany, assessed the bivalent candidate in comparison to the corresponding monovalent candidates targeting either variant in a mouse model.

Key Points: 
  • The preclinical study, conducted in collaboration with the Friedrich-Loeffler-Institut, Germany, assessed the bivalent candidate in comparison to the corresponding monovalent candidates targeting either variant in a mouse model.
  • During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals.
  • Notably, the bivalent Beta /Delta vaccine candidate induced two-fold higher virus neutralizing antibody titers against the Omicron variant than against the Delta variant in a rat model.
  • This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies.

DGAP-News: CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Retrieved on: 
Tuesday, April 12, 2022

By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation.

Key Points: 
  • By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation.
  • Under the contract, the federal government will pay CureVac and GSK an annual standby fee after successful completion of the setup period, which requires the companies to maintain manufacturing capacity at constant readiness.
  • By ensuring the availability of manufacturing capacities in Germany, the arrangement will significantly contribute to strengthening pandemic preparedness.
  • "We welcome this announcement of the German federal government, which aims to strengthen the country's preparedness against future pandemics," said Roger Connor, President of Vaccines and Global Health, GSK.